(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 December 2009 (17.12.2009)

PCT

(10) International Publication Number
WO 2009/152128 A1

(51) International Patent Classification:
A61K 38/28 (2006.01) *A61K 47/48* (2006.01)

(21) International Application Number:
PCT/US2009/046704

(22) International Filing Date:
9 June 2009 (09.06.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/061,281 13 June 2008 (13.06.2008) US
61/121,394 10 December 2008 (10.12.2008) US

(71) Applicant *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BEALS, John, Michael** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **CUTLER, Gordon, Butler** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **DOYLE, Brandon** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **HANSEN, Ryan, John** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **LI, Shun** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46033 (US). **SHIRANI, Shahriar** [CA/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). **ZHANG, Lianshan** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(74) Agents: **SHARP, Robert, L.** et al.; Eli Lilly And Company, Patent Division, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

[Continued on next page]

(54) Title: PEGYLATED INSULIN LISPRO COMPOUNDS

Figure 2



(57) Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.

WO 2009/152128 A1

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*